This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: I73.1 (thromboangiitis obliterans) | Special Copayment Reduction: V129 (rare disease) |
| B. Synonyms | Thromboangiitis obliterans [Buerger disease] |
| C. Adult onset | Possible first onset in adulthood: very high — thromboangiitis obliterans (Buerger disease) occurs almost exclusively in adults. The typical age of onset is under 40~50 years in male smokers, and symptoms of distal lower limb arterial occlusion first appear within several years to decades after starting smoking. It also occurs in female smokers, and its incidence is increasing. |
| 1. History | 1879 first description by Felix von Winiwarter → 1908 systematic pathological report by Leo Buerger → named 'Buerger disease' → strong association with smoking established. |
| 2. Causes | Smoking (cigarettes, e-cigarettes, cannabis) is the only established cause. An immune-mediated vasculitis mechanism is presumed to be involved. Genetic predisposition. |
| 3. Genetics | Associations with HLA-A9 and HLA-B5 reported. Not a genetic disease, but genetic predisposition exists. GWAS data limited. |
| 4. General epidemiology | High in male smokers in Eastern Europe, the Middle East, South Asia, and East Asia. Prevalence in the West is declining (in line with decreasing smoking rates). Prevalence in Korea about 0.5~2 per 100,000. |
| 5. Pathophysiology | Smoking → vascular endothelial dysfunction and immune activation → panvasculitis and thrombus formation in small and medium-sized arteries and veins → luminal occlusion. |
| 6. Symptoms | Intermittent claudication of the distal lower limb, rest pain, ischemic ulcers and gangrene of the feet and toes. Upper limb (hand, finger) involvement. Migratory superficial phlebitis. |
| 7. Signs | Absent distal pulses, Raynaud phenomenon, traces of migratory superficial phlebitis. Decreased ABI. Small vessel occlusion and corkscrew collateral vessels on vascular ultrasound and angiography. |
| 8. Screening | When distal ischemic symptoms appear in a smoker under age 40, perform ABI measurement and vascular studies immediately. Induce early smoking cessation. |
| 9. Diagnosis | Shionoya and Mills diagnostic criteria. ABI, vascular ultrasound, CTA/MRA, angiography (corkscrew collateral vessels). Exclude atherosclerosis and autoimmune disease. |
| 10. Treatment | Complete smoking cessation is the only curative treatment. Prostaglandins (intravenous iloprost). Revascularization (limited). Intensive management to prevent limb amputation. |
| 11. Prognosis | With smoking cessation, disease progression stops and the long-term prognosis is good. If smoking continues, the risk of major amputation is 30~40% (10 years). Cardiovascular mortality is lower than in general atherosclerosis. |
| 12. Prevention | Smoking cessation (absolute). Use of cessation aids and smoking cessation clinics. Prevention and early treatment of foot/hand wounds. Regular vascular examination. |
| 13. References | Olin JW. Thromboangiitis obliterans (Buerger's disease). N Engl J Med. 2000 … and 9 other papers |
The history of thromboangiitis obliterans (TAO), commonly known as 'Buerger's disease', goes back to the late 19th century. In 1879, the Austrian physician Felix von Winiwarter reported patients whose progressive occlusion of the lower limb arteries led to amputation and was the first to describe the unique histological findings of the arterial wall. However, it was Leo Buerger, a pathologist at Mount Sinai Hospital in New York, who systematically defined the disease in 1908; he analyzed in detail the amputation specimens of 11 patients (all young Eastern European Jewish immigrant men) and described it as an independent disease characterized by thrombosis and panvasculitis of small and medium-sized arteries and veins. Buerger named it 'thromboangiitis obliterans', and the disease later came to be called 'Buerger's disease' after him.
Initially, ethnic predisposition (Eastern European Jews) drew attention, but as higher prevalence was later confirmed in Asian and Middle Eastern populations, smoking emerged as the core cause. Since the mid-20th century, a strong association between smoking and TAO has been established by epidemiological studies, and prevalence has been observed to be high in countries and regions with high smoking rates and to decline with decreasing smoking rates. It has also been reported that e-cigarettes, cannabis, and chewing tobacco can cause TAO, suggesting that the components of tobacco smoke as a whole, rather than nicotine, are involved in the mechanism of vascular injury.
As research on immunological mechanisms became active in the late 20th century, it was revealed that TAO is not a simple thrombus-forming disease but an autoimmune vasculitis involving T-cell and B-cell-mediated immune responses. In terms of treatment, it has been established that complete smoking cessation is the only way to stop disease progression, and vasodilators such as intravenous prostaglandins (iloprost) have been shown to help relieve ischemic symptoms and heal ulcers. New approaches such as stem cell therapy and gene therapy are also being studied at the clinical trial stage.
The cause of thromboangiitis obliterans is not yet fully elucidated, but smoking is the only established cause. The association with smoking is supported by the following evidence: ① all TAO patients are smokers or have a smoking history, ② disease progression stops with complete smoking cessation, ③ relapse or worsening occurs when smoking resumes, and ④ prevalence is low in regions with low smoking rates and declines with decreasing smoking rates.
However, TAO occurs in only a minority of smokers, so smoking alone is not the whole cause. An abnormal immune response to smoking, that is, an immune-mediated vasculitis mechanism, is suggested to be involved. Evidence: ① infiltration of T cells, B cells, macrophages, and dendritic cells is observed in TAO lesions, ② anti-endothelial cell antibodies (AECA) against vascular endothelial cells are positive in about 50% of TAO patients, and ③ cell-mediated hypersensitivity to the collagen components of tobacco is observed. A pathway is suggested in which smoking components (probably tobacco collagen components) act as antigens to trigger an abnormal immune response, which leads to vascular endothelial injury → thrombus formation → vascular occlusion.
Recent case reports have confirmed that e-cigarette and cannabis smoking can also cause or worsen TAO. This suggests that the vascular toxicity of smoking itself, rather than a nicotine-specific effect, is important. Although a genetic predisposition (HLA association) exists, TAO is not classified as a genetic disease.
Thromboangiitis obliterans is not classified as a genetic disease and has no single-gene cause. However, a genetic predisposition appears to exist. In HLA (human leukocyte antigen) studies, HLA-A9 and HLA-B5 (especially HLA-Bw54) were found at a higher frequency in Japanese TAO patients than in controls, suggesting that a particular type of immune response is associated with TAO susceptibility. A similar HLA association has been reported in Korean patients, but independent validation is needed.
Individual differences in immune response to tobacco smoke components may be partly determined by HLA type, which may explain why only some people with the same smoking exposure develop TAO. An association between TAO and polymorphisms of blood coagulation-related genes (prothrombin variant, factor V Leiden, etc.) has also been suggested in some studies, but there is no reproducible conclusion. Genome-wide association studies (GWAS) have not been sufficiently performed in TAO, so comprehensive genetic data are limited.
Familial TAO is reported sporadically but is rare, and shared smoking habits rather than heredity are thought to be the main cause of clustering within families. Clinical genetic testing for TAO is not currently recommended. At diagnosis, young age, smoking history, and clinical pattern are more important diagnostic criteria.
The epidemiology of thromboangiitis obliterans varies greatly by region and era. Traditionally, prevalence is high in Eastern Europe, the Middle East, South Asia, and East Asia, consistent with the tendency toward high smoking rates in these regions. In Western Europe and North America, TAO prevalence has been steadily declining along with decreasing smoking rates.
The typical patient profile is a male smoker under 40~50 years of age. However, the occurrence of TAO in female smokers is increasing, and in some Western studies women make up 20~30% of the total. The most common age of onset is the 20s to 40s, and first onset after age 50 is relatively rare, so other causes must be excluded first.
Epidemiology in Korea lacks accurate nationwide data, but in vascular surgery practice TAO is estimated to account for about 10~20% of causes of peripheral arterial occlusion. Characteristics of TAO in Korea are that males are overwhelmingly predominant (more than 90%), lower limb involvement predominates, and the amputation rate with continued smoking is at a level similar to that in the West. TAO is registered as a rare disease eligible for special copayment reduction (V129). Particularly high prevalence is reported in India, Israel, and Japan, and in Israel a rate of 16.6 per 100,000 population was reported in the past.
In TAO patients, differentiation from peripheral arterial occlusive disease (PAOD) is important. TAO mainly involves small and medium-sized distal arteries (infrapopliteal arteries, forearm arteries, digital arteries) and occurs in young smokers without severe atherosclerosis, whereas PAOD mainly involves medium and large arteries (iliac artery, femoral artery) and is accompanied by risk factors such as advanced age, diabetes, and hyperlipidemia.
The core pathophysiology of thromboangiitis obliterans is non-necrotizing panarteritis of small and medium-sized arteries and veins together with thrombus formation. This is distinguished from the lipid accumulation and calcification seen in atherosclerosis, and is characterized by preservation of the internal elastic lamina.
Vascular endothelial dysfunction: tobacco smoke components (acrolein, polycyclic aromatic hydrocarbons, nitric oxide, etc.) directly damage vascular endothelial cells and increase oxidative stress. Damaged endothelial cells show reduced endothelium-dependent vasodilation (NO-mediated) and increased secretion of endothelin-1, promoting vasoconstriction and platelet aggregation. Increased carboxyhemoglobin from smoking further reduces tissue oxygen supply.
Immune-mediated vasculitis: on histopathology of lesional vessels, infiltration of T cells (CD4+, CD8+) and macrophages is observed in all vascular layers (intima, media, adventitia). Neutrophils also infiltrate in the acute phase. Immune cell infiltration also appears within the thrombus, which is a feature distinguishing it from other thrombotic diseases. Anti-endothelial cell antibodies (AECA) induce endothelial cell apoptosis, and complement activation amplifies vascular injury. There is a hypothesis that T cell-mediated hypersensitivity to tobacco collagen antigens causes cross-reactivity in the vascular endothelium.
Thrombus formation and luminal occlusion: vascular endothelial injury and the immune response activate platelets and the coagulation cascade, forming thrombi. Thrombi in the acute phase are rich in immune cells, and in the chronic phase the thrombus becomes organized and the lumen is replaced by fibrous tissue. The vascular adventitia is relatively preserved, with abundant surrounding inflammatory reaction.
Collateral vessel formation: on angiography, 'corkscrew' or spiral collateral vessels characteristically appear around the occluded segment. This is because collateral vessels become tortuous owing to spatial constraints as they develop, and it is an important angiographic finding for diagnosing TAO.
The clinical symptoms of thromboangiitis obliterans consist of distal ischemia from occlusion of small and medium-sized arteries and migratory superficial phlebitis.
Intermittent claudication: the most common early symptom. Unlike typical PAOD from femoral and popliteal artery occlusion, claudication in TAO is characterized by claudication of the foot and toes or forefoot (instep claudication), because TAO mainly involves below-the-knee arteries and foot arteries. With upper limb involvement, finger and palm pain occurs. As the claudication distance gradually shortens, it progresses to rest pain.
Rest pain and ischemic ulcers and gangrene: in advanced TAO, severe burning pain of the feet, toes, and fingertips appears even at rest. Skin color changes (cyanosis, pallor, dependent rubor = Buerger's three-color change) are observed. Ischemic ulcers mainly occur at the tips of the toes or around the nails, and the pain is extreme. Ulcers that do not heal can progress to dry or wet gangrene. Fingertip gangrene can also occur in the upper limbs.
Migratory superficial thrombophlebitis: a very characteristic symptom in TAO, occurring in about 40~50% of patients. Typically, linear erythema, tenderness, and induration appear along superficial veins of the dorsum of the foot or forearm, then improve and recur at other sites in a migratory pattern. When this finding appears in a young male smoker, TAO should be strongly suspected.
Raynaud's phenomenon: vasospasm occurs in which the fingers and toes show tricolor change (pallor → cyanosis → redness) on exposure to cold or stress. In TAO, Raynaud's phenomenon reflects underlying vascular occlusion rather than simple vasospasm, so its clinical course is more serious than that of primary Raynaud's phenomenon.
The physical signs of thromboangiitis obliterans reflect the consequences of distal vascular occlusion.
Pulse abnormalities: decreased or absent distal pulses in the affected limb are the most important sign. Absent dorsalis pedis and posterior tibial artery pulses are typical. In contrast, popliteal and femoral artery pulses are normal or only slightly decreased early on, and this combination (normal proximal + absent distal) is an important clinical clue to TAO. With upper limb involvement, radial or ulnar artery pulses are absent.
Skin changes: thinning of the skin, hair loss, nail dystrophy, and pallor or cyanosis are observed in ischemic areas. Buerger test (dependent rubor test): pallor on raising the leg 60 degrees in the supine position and dependent rubor in the lowered position suggest ischemia. Skin temperature is low, and ischemic ulcers or signs of early gangrene may appear at the toes or the tip of the foot.
Traces of migratory superficial phlebitis: pigmentation, sclerosis, and induration are observed along superficial veins of the forearm or dorsum of the foot. In the active phase, linear erythema, tenderness, and induration appear.
Vascular test findings: ankle-brachial index (ABI) falls to < 0.9. Vascular ultrasound shows multiple occlusions of small infrapopliteal arteries and collateral vessel formation. Characteristic corkscrew collateral vessels on angiography or CTA/MRA are the key imaging finding for diagnosis. Calcification and large vessel lesions common in atherosclerosis are rare or absent in TAO.
General population screening for thromboangiitis obliterans is not performed. However, a systematic approach for early detection in high-risk groups is important.
Early evaluation of high-risk groups: when distal claudication (foot/toe pain), rest pain in the feet/fingers, migratory superficial phlebitis, or Raynaud's phenomenon appears in a male smoker under 40~50 years of age, ABI measurement and vascular ultrasound should be performed immediately. Distal ischemic symptoms in a young person without atherosclerosis risk factors (diabetes, hyperlipidemia, hypertension) are a strong clue to TAO.
Smoking cessation guidance and monitoring: the most important preventive approach is strengthening smoking cessation education in adolescent and young adult smokers and preventing relapse to smoking in patients who have already tried to quit. Measurement of serum cotinine to confirm smoking cessation is used clinically.
Family screening: familial TAO is rare, but performing vascular testing at a lower threshold in young smokers with a parent or sibling with TAO is recommended. Genetic screening is not currently recommended clinically.
Diagnosis of thromboangiitis obliterans is based on characteristic clinical features and vascular imaging, and the process of excluding other vascular diseases (atherosclerotic PAOD, autoimmune vasculitis, embolism, etc.) is essential.
Shionoya diagnostic criteria: ① smoking history, ② onset before age 50, ③ infrapopliteal arterial occlusion, ④ upper limb involvement or migratory superficial phlebitis, ⑤ exclusion of causes of atherosclerosis and embolism such as diabetes, hyperlipidemia, hypertension, and autoimmune disease. There are various diagnostic criteria, including the Mills and Bhatt criteria, but all require distal occlusion + corkscrew collaterals + exclusion of other causes in a young smoker.
Vascular imaging: the degree of distal occlusion is assessed by ABI (ankle-brachial index) measurement. Vascular ultrasound noninvasively confirms infrapopliteal arterial occlusion and blood flow. CTA or MRA evaluates the vessels of both upper and lower limbs as a whole to confirm the distribution of occlusion (mainly infrapopliteal small vessels) and normality of the proximal large vessels. Corkscrew collateral vessels are characteristic on angiography (DSA), but CTA/MRA is now replacing it as the first-line tool.
Blood tests for differential diagnosis: autoantibodies (ANA, ANCA, antiphospholipid antibodies, anticardiolipin antibodies, rheumatoid factor), inflammatory markers (ESR, CRP), fasting glucose and lipid tests, blood cell count, coagulation function tests. If these tests are positive, other causes such as systemic vasculitis (polyarteritis nodosa, systemic lupus erythematosus), antiphospholipid syndrome, and embolism (atrial fibrillation, aneurysm) are excluded. A cotinine test confirms actual smoking status.
Cardiac and proximal vascular evaluation: echocardiography, ECG, and transesophageal echocardiography are performed to exclude distal embolism from intracardiac thrombus or atrial fibrillation. Atherosclerosis and aneurysm of proximal vessels (thoracoabdominal aorta, iliac arteries) must be excluded.
In the treatment of thromboangiitis obliterans, complete smoking cessation is the most important and the only curative treatment capable of stopping disease progression. All treatments other than smoking cessation are adjunctive for symptom relief and prevention of complications.
Complete smoking cessation: if smoking is stopped completely, disease progression stops in most cases and new ischemic events do not occur. Even a small amount of smoking, 1~2 cigarettes a day, can reactivate TAO, so complete cessation is essential. E-cigarettes, chewing tobacco, and cannabis can also cause or worsen TAO, so all tobacco and smoking products must be stopped completely. Use of cessation aids (varenicline, nicotine replacement therapy, bupropion) and smoking cessation clinics is recommended. Success of smoking cessation is confirmed by measuring serum cotinine.
Drug therapy: intravenous administration of prostaglandin derivatives (iloprost, a PGI2 analog) has been shown to be effective for healing ischemic ulcers and reducing rest pain, and when combined with smoking cessation it increases the rate of amputation avoidance. Intravenous infusion treatment is usually given for 2~6 hours/day, repeated over 2~4 weeks. The effect of oral prostaglandins and aspirin is weaker than that of intravenous iloprost, but they are used for long-term maintenance. The effect of anticoagulants (heparin, warfarin) is unclear, but they are sometimes used short term for acute thrombus formation. Calcium channel blockers (nifedipine) are used adjunctively to relieve Raynaud's phenomenon.
Revascularization: because TAO mainly involves small distal arteries, opportunities for surgical revascularization (bypass) are limited. When a suitable distal target vessel exists, distal bypass using autogenous vein grafts (saphenous vein) may be attempted, but when occlusion is extensive the success rate of recanalization is low and long-term patency is also low. Balloon angioplasty can also be attempted for focal occlusion, but experience is limited.
Amputation: when irreversible gangrene progresses and infection accompanies, amputation may be unavoidable. In patients who maintain smoking cessation, amputation is often limited to minor amputation (toe level), but with continued smoking it may progress to major amputation (below or above the knee). Continuing smoking cessation after amputation can greatly reduce the risk of amputation of the contralateral limb.
New treatment approaches: mesenchymal stem cell transplantation, bone marrow-derived cell transplantation, and vascular endothelial growth factor (VEGF) gene therapy are being studied at the clinical trial stage, and improvement in blood flow and ulcer healing has been reported in some cases. They have not yet been established as standard treatment.
The prognosis of thromboangiitis obliterans is determined by whether smoking is stopped. There is a dramatic difference in prognosis between patients who achieve complete smoking cessation and those who continue smoking.
Prognosis with smoking cessation: in most patients who maintain complete smoking cessation (about 90% or more), disease progression stops and new ischemic events do not occur. The risk of amputation is markedly reduced, and in some patients existing symptoms may also improve. The long-term survival rate of patients who succeed in quitting does not differ greatly from that of the general population. Unlike atherosclerotic PAOD, TAO rarely involves the coronary or cerebral vessels, so the risk of cardiovascular death is low.
Prognosis with continued smoking: if smoking continues, the disease keeps progressing and new vascular occlusions occur. A large cohort reported that the risk of major amputation within 10 years reaches about 30~40% with continued smoking. Recurrent ulcers, infection, and sepsis also increase morbidity. Even in patients who relapse to smoking after quitting, the disease can reactivate rapidly.
Psychological problems: depression and anxiety disorders from chronic pain, the threat of amputation, and loss of employment commonly accompany the disease. Maintaining smoking cessation, rehabilitation, and psychological support should be included in holistic management.
The most important thing in preventing thromboangiitis obliterans is not to start smoking, or to stop smoking completely immediately after diagnosis. This is the only way to prevent the onset and progression of the disease.
Primary prevention — smoking cessation: because smoking is the only established cause of TAO, not starting smoking is the most effective primary prevention. Public health policies such as smoking prevention education for adolescents, tobacco price policies, and regulation of smoking advertising contribute to population-level prevention of TAO. Physicians should actively offer smoking cessation counseling and adjunctive treatment to all smoking patients.
Prevention after diagnosis — complete smoking cessation: after TAO diagnosis, complete smoking cessation is the most effective way to prevent disease progression, amputation, and recurrence. Together with cessation aids such as nicotine patches, gum, varenicline (Chantix), and bupropion, smoking cessation clinics, cognitive behavioral therapy, and support groups are recommended. Regular cotinine measurement to confirm cessation is clinically useful.
Prevention of foot and hand wounds: in patients with distal ischemia, foot and finger wounds can be the starting point of ischemic ulcers and gangrene, so careful foot care (no tight shoes, nail care, foot inspection) is important. Keeping the feet and hands warm (wearing thick socks and gloves) and minimizing cold exposure also help prevent worsening of Raynaud's phenomenon. Narrow shoes and the elastic bands of socks can further restrict blood flow and should be avoided.
Regular follow-up: regular follow-up is important to confirm that smoking cessation is maintained (cotinine measurement), assess vascular status (ABI, vascular ultrasound), and detect and treat ulcers and gangrene early. New involvement of the contralateral limb or upper limbs is also monitored. Even after smoking cessation is achieved, existing occluded segments are not completely recanalized, so management of residual ischemia and preventive education must continue.
Olin JW. Thromboangiitis obliterans (Buerger's disease). N Engl J Med. 2000;343(12):864-869. DOI: 10.1056/NEJM200009213431207. PMID: 10995867.
Piazza G, Creager MA. Thromboangiitis obliterans. Circulation. 2010;121(14):1941-1950. DOI: 10.1161/CIRCULATIONAHA.110.955336. PMID: 20404258.
Buerger L. Thrombo-angiitis obliterans: a study of the vascular lesions leading to presenile spontaneous gangrene. Am J Med Sci. 1908;136:567-580. DOI: 10.1097/00000441-190810000-00011.
Dargon PT, Landry GJ. Buerger's disease. Ann Vasc Surg. 2012;26(6):871-880. DOI: 10.1016/j.avsg.2011.11.005. PMID: 22533967.
Malecki R, Zdrojowy K, Adamiec R. Thromboangiitis obliterans in the 21st century–a new face of disease. Atherosclerosis. 2009;206(2):328-334. DOI: 10.1016/j.atherosclerosis.2009.02.018. PMID: 19297000.
Sasajima T, Kubo Y, Inaba M, et al. Role of infrainguinal bypass in Buerger's disease: an eighteen-year experience. Eur J Vasc Endovasc Surg. 1997;13(2):186-192. DOI: 10.1016/S1078-5884(97)80154-2. PMID: 9091156.
Bozkurt AK, Koksal C, Demirbas MY, et al. A randomized trial of intravenous iloprost versus lumbar sympathectomy in the management of Buerger's disease. Int Angiol. 2006;25(2):162-168. PMID: 16763543.
Fazeli B, Ravari H, Farzadnia M. Does a species of Rickettsia play a role in the pathophysiology of Buerger's disease? Vascular. 2012;20(2):108-111. DOI: 10.1258/vasc.2011.cr0314. PMID: 22516560.
Isner JM, Baumgartner I, Rauh G, et al. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor. Ann Intern Med. 1998;128(7):552-558. DOI: 10.7326/0003-4819-128-7-199804010-00006. PMID: 9518399.
Kim DH, Ko YG, Ahn CM, et al. Immediate and 1-year outcomes of endovascular therapy for below-the-knee arterial occlusions in patients with Buerger's disease. J Endovasc Ther. 2014;21(1):77-83. DOI: 10.1583/13-4525R.1. PMID: 24502484.